Gerard Criner, MD, FACP, FACCP, professor and founding chair, Thoracic Medicine and Surgery, at the Lewis Katz School of Medicine at Temple University, discusses a new trial that investigated how long treatment would last for patients with emphysema, and if any complications arose.
Patients with emphysema had an opportunity to participate in a long-term trial, allowing outcomes to be measured over years instead of months, said Gerard Criner, MD, FACP, FACCP, professor and founding chair, Thoracic Medicine and Surgery, at the Lewis Katz School of Medicine at Temple University.
Today at the at the 2023 American Thoracic Society International Conference, Criner presented long-term data on the EMPROVE trial, which investigated benefits of the Spiration Valve System in patients who have emphysema.
Transcript
Why did you decide to study this topic?
Patients with emphysema suffer from hyperinflation, and that hyperinflation has a significant contribution to the morbidity and mortality of the disease. Over the last 20 years, various attempts of trying to decrease the degree of hyperinflation have included medicines, plus other surgical and less-invasive forms of therapy. There are bronchoscopic techniques; the ones that are approved in the United States are in the endobronchial valves. [The] EMPROVE study was a prospective randomized multicenter controlled trial that was conducted in patients who were hyperinflated with emphysema to see if lobar occlusion could decrease the amount of air trapping and could result in improving the patient outcome measured by improvements in lung function, quality of life, [and] reduction in shortness of breath.
Most of the therapies that have looked at this range of treatments are really focused at patients that are 3 months, 6 months, 12 months in outcome. But when it's brought into clinical practice, the questions that patients ask and providers ask, [is] “How long do these effects last?”
So, the genesis of this long-term evaluation was a look at the durability of the treatment effect, see if it remains, as well as looking at the complications as a result of the therapy in a cohort of patients that were followed up to 5 years after the treatment.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More